These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7893906)

  • 1. Isoniazid is not always the cause of hepatitis during treatment of tuberculosis.
    van der Kooi K; Mottet JJ; Regamey C
    Clin Infect Dis; 1994 Nov; 19(5):987-8. PubMed ID: 7893906
    [No Abstract]   [Full Text] [Related]  

  • 2. Pyrazinamide-induced granulomatous hepatitis.
    Knobel B; Buyanowsky G; Dan M; Zaidel L
    J Clin Gastroenterol; 1997 Jun; 24(4):264-6. PubMed ID: 9252856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Isoniazid-induced hepatic failure. Report of a case].
    Pereira RM; Tresoldi AT; Hessel G
    Arq Gastroenterol; 2000; 37(1):72-5. PubMed ID: 10962632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic complications of antituberculosis therapy revisited.
    Cohen CD; Sayed AR; Kirsch RE
    S Afr Med J; 1983 Jun; 63(25):960-3. PubMed ID: 6857425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrazinamide-isoniazid: its apparent influence on the reactivation rate in pulmonary tuberculosis.
    Phillips S
    Am Rev Respir Dis; 1967 Mar; 95(3):503-5. PubMed ID: 6066869
    [No Abstract]   [Full Text] [Related]  

  • 6. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
    de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
    Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Liver injury under tuberculostatic treatment].
    Fattinger K; Braunschweig S; Reichen J; Meier-Abt PJ; Krähenbühl S
    Praxis (Bern 1994); 1997 Apr; 86(15):626-9. PubMed ID: 9213916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
    van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
    Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fulminant hepatitis induced by pyrazinamide].
    Roden S; Lagneau M; Homasson JP
    Rev Pneumol Clin; 1990; 46(1):43. PubMed ID: 2371480
    [No Abstract]   [Full Text] [Related]  

  • 11. [A clinical investigation of seven patients with pulmonary tuberculosis who developed mixed liver injury during oral anti-tuberculosis treatment].
    Nomi F; Hosaka K; Kurosawa T
    Kekkaku; 2013 Sep; 88(9):647-51. PubMed ID: 24298690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of drug-induced hepatitis occurring in elderly and younger patients during anti-tuberculosis treatment with a regimen including pyrazinamide].
    Miyazawa N; Horita N; Tomaru K; Tsukahara T; Takahashi R; Sasaki M; Ishigatsubo Y
    Kekkaku; 2013 Mar; 88(3):297-300. PubMed ID: 23672170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of tuberculosis in patients with pre-existing liver disease or following hepatotoxic drug reactions.
    Robson SC; Pillans P; Willcox PA
    S Afr Med J; 1993 Jun; 83(6):432-4. PubMed ID: 8211464
    [No Abstract]   [Full Text] [Related]  

  • 14. A comparison of regimens of ethionamide, pyrazinamide and cycloserine in re-treatment of patients with pulmonary tuberculosis.
    Bignall JR; Lind A; Rist N
    Bull Int Union Tuberc; 1969 Aug; 42():7-57. PubMed ID: 5004884
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population.
    Neill P; Pringle D; Mhonda M; Kusema T; Nhachi CF
    Cent Afr J Med; 1990 Apr; 36(4):104-7. PubMed ID: 2225025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation.
    Farrell FJ; Keeffe EB; Man KM; Imperial JC; Esquivel CO
    Dig Dis Sci; 1994 Oct; 39(10):2255-9. PubMed ID: 7924752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis cases in isoniazid treated groups and in a control group.
    Riska N
    Bull Int Union Tuberc; 1976; 51(1):203-8. PubMed ID: 1030282
    [No Abstract]   [Full Text] [Related]  

  • 18. Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal.
    P V K; Palaian S; Ojha P; P R S
    Pak J Pharm Sci; 2008 Jan; 21(1):51-6. PubMed ID: 18166520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letter: Isoniazid hepatitis.
    Badger TL; Levy SA; Stead WW; Alonso K; Starke WR
    Ann Intern Med; 1973 Nov; 79(5):751-2. PubMed ID: 4751753
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter: Isoniazid hepatitis.
    Stein SC
    Ann Intern Med; 1974 Mar; 80(3):423-4. PubMed ID: 4816197
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.